<DOC>
	<DOCNO>NCT00085397</DOCNO>
	<brief_summary>RATIONALE : Vaccines make patient 's dendritic cell may make body build immune response kill tumor cell . It yet know whether combine vaccine therapy either gp100 antigen patient 's tumor cell cause strong immune response kill tumor cell . PURPOSE : This randomized phase II trial study vaccine therapy gp100 antigen see well work compare vaccine therapy patient 's tumor cell treat patient stage III stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare tumor-specific immune response , term number gp100-specific cytotoxic T-lymphocytes , T-cell production interferon gamma , T-cell proliferation response vitro exposure gp100 tumor lysate , patient stage III IV melanoma treat autologous dendritic cell ( DC ) pulse gp100 antigen v autologous DC fuse autologous tumor cell . Secondary - Compare safety toxicity regimens patient . - Compare therapeutic effect regimens patient . OUTLINE : This randomize study . Patients randomize 1 2 treatment arm . All patient undergo leukapheresis . Peripheral blood mononuclear cell culture generate dendritic cell ( DC ) . - Arm I : Patients undergo surgical harvesting tumor cell subsequent fusion . Patients receive vaccination comprise DC fuse autologous tumor cell subcutaneously day 1 . Treatment repeat every 21 day 3 course . Patients achieve partial ( PR ) complete response ( CR ) may receive additional 3 course . - Arm II : Patients receive vaccination comprise DC pulse gp100 antigen IV day 1 . Treatment repeat every 21 day 6 course . Patients achieve PR CR may receive additional 6 course . In arm , patient follow monthly 6 month . PROJECTED ACCRUAL : A total 40 patient ( 20 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cutaneous melanoma Stage III IV disease Recurrent de novo stage III disease allow disease unresectable definitive treatment available gp100 HLAA201positive Surgically accessible tumor , define 1 following : Pulmonary lesion approachable thoracoscopic procedure Skin superficial soft tissue lymph node lesion amenable resection local anesthesia Malignant ascites pleural effusion Measurable disease addition surgically accessible tumor &gt; 2.0 cm No CNS metastases No mucosal ocular melanoma PATIENT CHARACTERISTICS : Age Any age Performance status ECOG 01 Life expectancy More 3 month Hematopoietic WBC &gt; 3,000/mm^3 Platelet count &gt; 75,000/mm^3 Hepatic Bilirubin &lt; 2.0 mg/dL Renal Creatinine &lt; 2.0 mg/dL Immunologic No active infection require treatment No clinically significant autoimmune disorder No immune deficiency disorder HIV negative Other Antecubital vein accessible leukapheresis No malignancy within past 5 year except nonmelanoma skin cancer squamous cell carcinoma situ cervix No preexist comorbid disease would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception PRIOR CONCURRENT THERAPY : Biologic therapy No prior melanoma vaccine therapy More 6 week since prior immunotherapy Chemotherapy No prior chemotherapy metastatic melanoma Endocrine therapy No concurrent corticosteroid Radiotherapy More 6 week since prior radiotherapy Surgery Not specify Other No concurrent systemic immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>